Mirrors of Medicine library
In the spotlight
Progression after IO for RCC: What's next?
Presentor: Lisa Pickering
Learning objective: Learn about promising post-IO strategies for RCC progression, including HIF-2α inhibitors and novel targets such as LAG3, CAR-T, TIGIT, and PARP, despite limited evidence for IO rechallenge.
How to approach an mHSPC patient: Insights from clinical practice
Presentor: Amit Bahl
Tailor mHSPC treatment by counseling patients on all treatment options, proactively managing adverse events to optimize outcomes/quality of life, and leveraging multidisciplinary care.
Tailoring first-line treatment strategies for advanced bladder cancer: Toward individualised care
Moderator: Géraldine Pignot
Presenter: Daniel Raggi
Learning objective: Acknowledge the first-line standards for advanced/metastatic bladder cancer, the ongoing relevance of chemotherapy + IO in selected cases, and clinical characteristics and key biomarkers that guide individualised care.
RENALC meets BLADDR: When to stop IO?
Moderator: Ignacio Duran
Panel: Philippe Barthélémy, Raquel Brás, Sylvie Rottey, Bernadett Szabados
Learning objective: Gain insights into real-life bladder and renal cancer cases where discontinuation of immunotherapy may be appropriate, through an interactive case-based panel discussion.
Personalised adjuvant immunotherapy in MIBC and the impact of ctDNA testing
Moderator: Petros Grivas
Presenter: Thomas Powles (remote)
Learning objective: By reviewing latest congress highlights data, recognise the impact of ctDNA testing, and learn how to tailor adjuvant immunotherapy on a patient-specific level.
Metastatic pRCC: translating current evidence into clinical decision-making
Moderator: Sylvie Rottey
Case presenter: Ignacio Durán
Panel: Ignacio Durán, Lisa Pickering, Thomas Powles (virtual)
Learning objective: Trace papillary RCC evolution from classification to molecular features and treatments. Get up-to-date approaches to treat advanced clinical cases, and catch a glimpse of future therapies.
Precision strategies in mHSPC: State of the art and future directions
Moderator: Mário Fontes-Sousa
Presenters: Nuno Vau, David Olmos
Review the current treatment approaches in mHSPC and learn how to optimise outcomes. Understand how to integrate genomic profiling to guide emergent therapies in mHSPC.
From risk stratification to management: Contemporary strategies for NMIBC
Moderator: Félix Guerrero-Ramos
Presenter: Laura Mertens
Learning objective: Review low-/intermediate-/high-risk NMIBC definitions, learn about BCG failure categories and novel therapeutic approaches post-BCG from key trials.
Molecular diagnostics in motion: Liquid biopsies and tissue testing in mCRPC
Moderator: Derya Tilki
Presenter: David Olmos
Learning objective: Understand why targeted therapies require molecular selection and prioritise testing: somatic vs germline, biopsy/plasma strengths/limits, basic sequencing principles, and molecular targets.
